These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

755 related items for PubMed ID: 19180726

  • 1. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P.
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [Abstract] [Full Text] [Related]

  • 2. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
    Shi JY, Xu YC, Shi Y, Lü HX, Liu Y, Zhao WS, Chen DM, Xi LY, Zhou X, Wang H, Guo LN.
    Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
    [Abstract] [Full Text] [Related]

  • 8. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M, Bastide JM, Blancard A, Bonnin A, Bretagne S, Cambon M, Chandenier J, Chauveau V, Couprie B, Datry A, Feuilhade M, Grillot R, Guiguen C, Lavarde V, Letscher V, Linas MD, Michel A, Morin O, Paugam A, Piens MA, Raberin H, Tissot E, Toubas D, Wade A.
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [Abstract] [Full Text] [Related]

  • 9. In vitro antifungal susceptibility of clinical species belonging to Aspergillus genus and Rhizopus oryzae.
    Kachuei R, Khodavaisy S, Rezaie S, Sharifynia S.
    J Mycol Med; 2016 Mar; 26(1):17-21. PubMed ID: 26852191
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
    Espinel-Ingroff A.
    J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).
    Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Pelaez T, Pfaller MA, Rinaldi MG, Canton E, Turnidge J.
    J Clin Microbiol; 2010 Sep; 48(9):3251-7. PubMed ID: 20592159
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J, Peláez T, Alcalá L, Bouza E.
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
    [Abstract] [Full Text] [Related]

  • 16. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
    Espinel-Ingroff A, Johnson E, Hockey H, Troke P.
    J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
    [Abstract] [Full Text] [Related]

  • 17. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J, Peláez T, Alcalá L, Bouza E.
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
    [Abstract] [Full Text] [Related]

  • 18. In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of Aspergillus Nigri Complex.
    Badali H, Fakhim H, Zarei F, Nabili M, Vaezi A, Poorzad N, Dolatabadi S, Mirhendi H.
    Mycopathologia; 2016 Apr; 181(3-4):235-40. PubMed ID: 26615417
    [Abstract] [Full Text] [Related]

  • 19. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
    Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH.
    J Clin Microbiol; 1999 Dec; 37(12):3946-51. PubMed ID: 10565912
    [Abstract] [Full Text] [Related]

  • 20. Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
    Perkhofer S, Lugger H, Dierich MP, Lass-Flörl C.
    Antimicrob Agents Chemother; 2007 Feb; 51(2):791-3. PubMed ID: 17116665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.